Sugi Predict

Sugi Predict / Compounds / SCHEMBL5790190

SCHEMBL5790190

SCHEMBL5790190

O=c1[nH]c(=O)c2c(-c3ccccc3)csc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ ALDH1A1 P00352 7/20 0.46
▸ KDM4E B2RXH2 4/20 0.46
▸ LMNA P02545 3/20 0.46
▸ KMT2A Q03164 3/20 0.45
▸ POLB P06746 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ SENP8 Q96LD8 1/20 0.45
▸ SENP7 Q9BQF6 1/20 0.45
▸ SENP6 Q9GZR1 1/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ PRKAB2 O43741 1/20 0.44
▸ PRKAG1 P54619 1/20 0.44
▸ PRKAA2 P54646 1/20 0.44
▸ PRKAA1 Q13131 1/20 0.44
▸ PRKAG3 Q9UGI9 1/20 0.44
▸ PRKAG2 Q9UGJ0 1/20 0.44
▸ PRKAB1 Q9Y478 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5791467 0.84 ALDH1A1 (0.50) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL2897388 0.73 PRKAB2 (0.47) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL1118976 0.73 PRKAB2 (0.56) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL9097540 0.72 ERCC1 (0.48) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL16163675 0.72 ALDH1A1 (0.45) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL9398179 0.72 ADRA1D (0.51) ALDH1A1KDM4EKMT2APOLBMAPT
SCHEMBL1190759 0.71 PRKAB2 (0.54) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL1191531 0.71 PRKAB2 (0.54) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL5919066 0.71 PRKAG1 (0.82) ALDH1A1KDM4EPRKAB2PRKAG1PRKAA2
SCHEMBL1190782 0.70 PRKAB2 (0.50) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115151550-B External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof 桑福德·伯纳姆·普雷比医学发现研究所 2024-11-22 — — CN disclosed
US-20230121698-A1 ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2023-04-20 — — US disclosed
EP-4081528-A1 ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2022-11-02 — — EP disclosed
WO-2021133915-A1 ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2021-07-01 — — WO disclosed
WO-2021133915-A1 ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2021-07-01 — — WO disclosed
US-9249155-B2 Thieno [2, 3-D] pyrimidine derivatives and their use to treat arrhythmia XENTION LIMITED (GB) 2016-02-02 — — US disclosed
US-9249155-B2 Thieno [2, 3-D] pyrimidine derivatives and their use to treat arrhythmia XENTION LIMITED (GB) 2016-02-02 — — US disclosed
US-9249155-B2 Thieno [2, 3-D] pyrimidine derivatives and their use to treat arrhythmia XENTION LIMITED (GB) 2016-02-02 — — US disclosed
EP-2694518-B1 THIENO[2,3-D]PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA XENTION LTD (GB) 2015-10-07 — — EP disclosed
EP-2694518-B1 THIENO[2,3-D]PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA XENTION LTD (GB) 2015-10-07 — — EP disclosed
US-20140206703-A1 THIENO [2, 3-D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA XENTION LIMITED (GB) 2014-07-24 — — US disclosed
US-20140206703-A1 THIENO [2, 3-D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA XENTION LIMITED (GB) 2014-07-24 — — US disclosed
US-20140206703-A1 THIENO [2, 3-D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA XENTION LIMITED (GB) 2014-07-24 — — US disclosed
EP-2694518-A1 THIENO [2, 3 -D]PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA Xention Limited (GB) 2014-02-12 — — EP disclosed
WO-2012131379-A1 THIENO [2, 3 -D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA XENTION LIMITED (GB) 2012-10-04 — — WO disclosed
WO-2012131379-A1 THIENO [2, 3 -D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA XENTION LIMITED (GB) 2012-10-04 — — WO disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 — — EP disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230121698-A1 ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF ENPP1, ENPP3, PPA1 SMN1; SMN2 3049/4885NPC1 2739/4885RAB9A 960/4885
US-20140206703-A1 THIENO [2, 3-D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA KCNJ2, KCNH2, KCNH1 SMN1; SMN2 3235/4885NPC1 1846/4885RAB9A 2952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.